Company intelligence / Profile preview

Provention Bio

Red Bank, New Jersey, United Statespedsendo.org ↗

Ownership: Private
Development stage: Commercial

Overview

TZIELD (teplizumab-mzwv) was approved in the United States as the first and only therapy to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D[6]. The company's lead product TZIELD is currently being evaluated in a Phase 3 trial (PROTECT) for treatment of newly diagnosed clinical T1D with results expected in the second half of 2023[6].

Therapeutic areas: GastroenterologyEndocrinologyImmunology
Modalities: Monoclonal antibodiesvaccines
Industry: Biotech

Drug pipeline

1 asset

teplizumab

Commercial

Indications: Type 1 diabetes

Partnerships

SanofiAmgen Inc.MacroGenics Inc.Vactech OyHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Provention Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Provention Bio.

Explore the full profile